NCT03454503View on ClinicalTrials.gov

Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt

CompletedOBSERVATIONAL
Enrollment

173

Participants

Timeline

Start Date

May 13, 2018

Primary Completion Date

December 28, 2020

Study Completion Date

December 28, 2020

Conditions
Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase
Interventions
DRUG

Imatinib

Film coated tablet contains 400 mg imatinib (as mesilate)

Trial Locations (1)

11796

National Cancer Institute (NCI), Cairo

Sponsors
All Listed Sponsors
lead

Hikma Pharmaceuticals LLC

INDUSTRY